Future of Biotransformation Science in the Pharmaceutical Industry
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (3) , 258-267
Abstract
Over the past decades, the number of scientists trained in departments dedicated to traditional medicinal chemistry, biotransformation and/or chemical toxicology have seemingly declined. Yet, there remains a strong demand for such specialized skills in the pharmaceutical industry, particularly within drug metabolism/pharmacokinetics (DMPK) departments. In this position paper, the members of the Biotransformation, Mechanisms, and Pathways Focus Group (BMPFG) steering committee reflect on the diverse roles and responsibilities of scientists trained in the biotransformation field in pharmaceutical companies and contract research organizations. The BMPFG is affiliated with the International Society for the Study of Xenobiotics (ISSX) and was specifically created to promote the exchange of ideas pertaining to topics of current and future interest involving the metabolism of xenobiotics (including drugs). The authors also delve into the relevant education and diverse training skills required to successfully nurture the future cohort of industry biotransformation scientists and guide them towards a rewarding career path. The ability of scientists with a background in biotransformation/organic chemistry to creatively solve complex drug metabolism problems encountered during research and development efforts on both small molecule or large molecular modalities is exemplified in five relevant case studies. Finally, the authors stress the importance and continued commitment to training the next generation of biotransformation scientists who are not only experienced in the metabolism of conventional small molecule therapeutics, but are also equipped to tackle emerging challenges associated with new drug discovery modalities including peptides, protein degraders and antibodies. Significance Statement Biotransformation and mechanistic drug metabolism scientists are critical to advancing chemical entities through discovery and development, yet the number of scientists academically trained for this role is on the decline. This position paper highlights the continuing demand for biotransformation scientists and the necessity to nurture creative ways to train them and guarantee the future growth of this field.Keywords
This publication has 46 references indexed in Scilit:
- Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug designEuropean Journal of Medicinal Chemistry, 2012
- Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessaryXenobiotica, 2012
- Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase InhibitorsJournal of Medicinal Chemistry, 2011
- Managing the challenge of chemically reactive metabolites in drug developmentNature Reviews Drug Discovery, 2011
- Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory PotencyClinical Pharmacology & Therapeutics, 2010
- Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibodyAnalytical Biochemistry, 2009
- Human radiolabeled mass balance studies: objectives, utilities and limitationsBiopharmaceutics & Drug Disposition, 2009
- Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formationBioorganic & Medicinal Chemistry Letters, 2008
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Organic Chemistry in Drug DiscoveryScience, 2004